Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25: The SEMA-VR CardioLink-15 Trial
Author(s): Subodh Verma Added: 8 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device
Author(s): Michael R Zile Added: 1 year ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had… View more

Heart Failure
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Kidney Metabolic
Cardiovascular Risk in Asian Immigrants in the UK
Author(s): Sachin G Nair , Aishwarya Lakshmi Vidyasagaran , Mohammadrafi Damirchi , et al Added: 1 month ago

Prevention & Chronic Conditions
SOUL: Oral Semaglutide Improves CV Risk Factors in T2D
Added: 3 weeks ago Source:  Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse… View more

Cardiovascular Kidney Metabolic

Heart Failure
Diagnosing Hypertrophic Cardiomyopathy with Dr Sara Saberi
Author(s): Sara Saberi Added: 7 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi… View more

Heart Failure
Semaglutide May Aid Vascular Repair in High-Risk Patients
Added: 1 month ago Source:  Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹… View more

Cardiovascular Kidney Metabolic
COVID-19 and Acute Aortic Dissection: Early Outcomes
Author(s): An Thai Nguyen , Hau Tien Nguyen , Vu Tuan Le Added: 1 week ago

Intervention

Vascular Disease and Surgery
AHA 25: The OCEAN Trial
Author(s): Atul Verma Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter… View more

Anticoagulation

Electrophysiology & Arrhythmia
Win Ratio and Causal Methods in Asian Heart Failure Registries
Author(s): Porntep Amornritvanich , Amarit Tansawet Added: 4 days ago

Guidelines & Statements

Heart Failure